Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir

Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruse...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 204; no. 11; p. 1811
Main Authors:	Canducci, Filippo, Ceresola, Elisa R, Boeri, Enzo, Spagnuolo, Vincenzo, Cossarini, Francesca, Castagna, Antonella, Lazzarin, Adriano, Clementi, Massimo
Format:	Journal Article
Language:	English
Published:	United States 01.12.2011
Subjects:	Amino Acid Substitution - genetics Anti-HIV Agents - pharmacology Drug Resistance, Viral - genetics Heterocyclic Compounds, 3-Ring - pharmacology HIV Infections - drug therapy HIV Infections - virology HIV Integrase - genetics HIV Integrase Inhibitors - pharmacology HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics Humans Inhibitory Concentration 50 Microbial Sensitivity Tests Mutation Phenotype Pyrrolidinones - pharmacology Raltegravir Potassium
ISSN:	1537-6613, 1537-6613
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!